Sumitomo Dainippon Pharma Signs a Co-Promotion & Commercialization Agreement with Novartis for Diabetes in Japan
Shots:
- Novartis to receive upfront from Sumitomo. Sumitomo to get rights to co-promote Novartis’ Equa and EquMet from July’19 in addition to distribution rights from Nov’19- receiving payment for promotion & commercialization in Japan
- The focus of the collaboration is to expand Sumitomo’s diabetes portfolio in Japan and is expected to generate annual revenue of ~$1.8M
- Equa (50mg) is an oral DPP-4 inhibitor- inhibiting glucagon secretion by increasing the conc. of GLP-1. EquMet is a combination of DPP-4 inhibitor and biguanide- effectively lowers blood sugar level by stimulating insulin secretion & improving insulin resistance
Ref: Sumitomo Dainippon Pharma | Image: The Hindu Business Line
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com